stroke. The American Heart Association in collaboration with the In-ternational Liaison Committee on Resuscitation. Circulation 2000;
102(8 Suppl): I204–I216.
43. http://jsa-web.org/stroke/index.html
44. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early re-current stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432–1442.
45. Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disabil-ity and hospital costs (EXPRESS study): a prospective popula-tion-based sequential comparison. Lancet Neurol 2009; 8: 235–243.
46. Lavallee PC, Meseguer E, Abboud H, et al. A transient ischaemic at-tack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007; 6: 953–960.
47. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after tran-sient ischaemic attack. Lancet 2007; 369: 283–292.
48. 阿部康二. 一過性脳虚血発作（TIA）．循環器内科2010; 10: 126–132.
49. 後藤文男．日本脳卒中学会・脳卒中重症度スケール（急性期）
の発表にあたって．脳卒中1997; 19: 1–5.
50. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.
Stroke1994; 25: 2220–2226.
51. Smith WS, Sung G, Saver J, et al. Mecahnical thrombetocmy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205–1212.
52. Yasaka M, Yamaguchi T, Oita J, et al. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke 1993; 24: 1681–
1685.
53. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23: 531–
54. 大友英一，沓沢尚之，小暮久也，他．脳血栓症急性期における534.
OKY-046の臨床的有用性―プラセボを対照とした多施設二重盲
検試験―．臨医薬 1991; 7: 353–388.
55. 篠原幸人，小川彰，鈴木則宏，他；脳卒中合同ガイドライン委員 会/日本脳卒中学会/日本脳神経外科学会/日本神経学会/日本 神経治療学会/日本リハビリテーション医学会）編．脳卒中治療 ガイドライン2009．協和企画，2009.
55a. Mohr JP, Thompson JL, Lazar RM, et al; Warfarin-Aspirin Recur-rent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;
345: 1444–1451.
55b. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial steno-sis. N Engl J Med 2005; 352: 1305–1316.
56. Connnoly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus war-farin in patients with atrial fibrillation. N Engl J Med 2009; 361:
1139–1151.
57. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaan versus warfarin in nonvalvular atrial finrillation. N Engl J Med 2011; 365: 883–891.
58. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:
981–992.
59. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose ator-vastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559.
60. Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008; 39: 2929–2935.
61. Soo YO, Yang SR, Lam WW, et al. Risk vs benefit of anti-thrombot-ic therapy in ischemanti-thrombot-ic stroke patients with cerebral manti-thrombot-icrobleeds. J Neurol 2008; 255: 1679–1686.
62. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical car-diovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459–467.
63. Kitagawa K, Hougaku H, Yamagami H, et al; OSACA2 Study Group. Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis 2007; 24: 35–42.
64. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thick-ness progression to predict cardiovascular events in the general pop-ulation (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053–2062.
65. Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy--an evidence-based review: report of the therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology.
Neurology 2005; 65: 794–801.
66. Sacco R, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:
a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:
Co-sponsored by the Council on Cardiovascular Radiology and In-tervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577–617.
67. Rothwell P, Eliasziw M, Gutnikov S, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915–924.
68. Alamowitch S, Eliasziw M, Barnett H, et al. The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke 2005; 36: 27–31.
69. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients with-out recent neurological symptoms: randomized controlled trial. Lan-cet 2004; 363: 1491–1502.
70. Abott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: rsults of a systematic review and analysis. Stroke 2009; 40:
e573–e583.
71. Yadav J, Wholey M, Kuntz R, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;
351: 1493–1501.
72. Bates ER, Babb JD, Casey DE Jr, et al. ACCF/SCAI/SVMB/SIR/
ASITN 2007 clinical expert consensus document on carotid stent-ing: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/
SVMB/SIR/ASITN Clinical Expert Consensus Document Commit-tee on Carotid Stenting). Am Coll Cardiol 2007; 49: 126–170.
73. Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterec-tomy for treatment of carotid-artery stenosis. N Engl J Med 2010;
363: 11–23.
74. 篠原 幸人，吉本 高志，福内 靖男，他；脳卒中合同ガイドライン 委員会（日本脳卒中学会/日本脳神経外科学会（脳卒中の外科学 会）/日本神経学会/日本神経治療学会/日本リハビリテーショ ン医学会）編集．脳卒中治療ガイドライン2004．協和企画，
2004.
75. JET Study Group. Japanese EC-IC Bypass Trial (JET Study)：中間 解析結果（第二報）．脳卒中の外 2002; 30: 434–437.
76. Powers WJ, Clarke WR, Grubb RL, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral isch-emia. JAMA 2011; 306: 1983–1992.
77. 日本脳卒中の外科学会．科学的根拠に基づくくも膜下出血診療 ガイドライン．日本脳卒中の外科学会，2003.
78. Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (IATF) of neurosurgical clipping versus endovascu-lar coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360: 1267–1274.
79. 脳ドックの新ガイドライン作成委員会．脳ドックのガイドライ
ン2014［改訂・第4版］．日本脳ドック学会，2014．
80. Morita A, Kirino T, Hashi K, et al; UCAS Japan Investigators. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 2012; 366: 2474–2482.
81. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Eng J Med 1991; 325: 445–453.
82. Wilcox R, Bousser M, Betteridge D, et al; PROactive Investigators.
Effects of pioglitazone in patients with or without previous stroke:
results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865–873.
83. Amarenco P, Labreuche J, Lavallee P, et al. Statin in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 2004; 35: 2902–2909.
84. Adams HJ, del-Zoppo G, Albers M, et al. Guidelines for the early managemnt of patients with ischemic stroke. A guideline from the American Heart Assciation/Americal Stroke Association Stroke Counicl, Clinical Cardiology Council, Cardiovascular Radiology and Intevention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdiciplinary Working Group. Circulation 2007; 115: e478–e534.
85. Steinhubl SR, Berger PB, Mann JT, 3rd, et al; CREDO Investigators.
Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;
288: 2411–2420.
86. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001; 345: 494–502.
87. Levine GN, Jeong YH, Goto S, et al. Expert consensus document:
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11: 597–606.
88. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9–19.
89. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.
90. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.
91. Morrow DA, Braunwald E, Bonaca MP, et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:
1404–1413.
92. Diener HC, Bogousslavsky J, Brass LM, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–337.
93. Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.
94. Dewilde WJ, Oirbans T, Verheugt FW, et al; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial.
Lancet 2013; 381: 1107–1115.
95. Kinlay S, Schwartz GG, Olsson AG, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 2008; 28: 142–147.
96. Park KL, Budaj A, Goldberg RJ, et al; GRACE Investigators. Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]). Am J Cardiol 2012; 110: 628–635.
97. Bangalore S, Qin J, Sloan S, et al; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010; 122: 2142–2151.
98. Collaborative overview of randomised trials of antiplatelet therapy --I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81–106.
99. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;
324: 71–86.
100. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.
101. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.
102. Shinohara Y, Katayama Y, Uchiyama S, et al; CSPS 2 group.
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959–968.
103. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008; 47:
330–336.
104. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482–490.
105. James SK, Storey RF, Khurmi NS, et al; PLATO Study Group.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Circulation 2012; 125: 2914–2921.
106. Morrow DA, Alberts MJ, Mohr JP, et al. Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013; 44: 691–698.
107. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699–708.
108. Barrios V, Escobar C. Importance of blood pressure control in hypertensive patients with coronary heart disease in clinical practice to reduce the risk of stroke. Stroke 2009; 40: e469; author reply e470.
109. Mechtouff L, Touze E, Steg PG, et al; REACH Registry Investigators. Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease. J Intern Med 2010; 267: 621–633.
110. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33: 2722–2727.
111. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817–821.
112. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibril-lation. N Engl J Med 2013; 369: 2093–2104.
113. Hori M, Connolly SJ, Ezekowitz MD, et al. RE-LY Investigators.
Efficacy and safety of dabigatran vs. Warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800–805.
114. Hori M, Matsumoto M, Tanahashi N, et al; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J 2012; 76:
2104–2111.
115. Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447–451.
116. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.
117. Mehta RH, Dabbous OH, Granger CB, et al; GRACE Investigators.
Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003; 92: 1031–
1036.
118. Selim M. Perioperative stroke. N Engl J Med 2007; 356: 706–713.
119. Charlesworth D, Likosky D, Marrin C, et al. Development and validation of a prediction model for strokes after coronary artery bypass grafting. Ann Thorac Surg 2003; 76: 436–443.
120. Eagle K, Guyton R, Davidoff R, et al. ACC/AHA guidelines for cor-onary artery bypass graft surgery: executive summary and recom-mendations: A report of the American College of Cardiology/Ameri-can Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation 1999; 100: 1464–1480.
121. Mérie C, Køber L, Olsen PS, et al. Risk of stroke after coronary artery bypass grafting: effect of age and comorbidities. Stroke 2012;
43: 38–43.
121a. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guide-line for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Asso-ciation Task Force on Practice Guidelines. Circulation 2011; 124:
e652–e735.
122. Miyata S. Heparin-induced thrombocytopenia. ISBT Science Series 2009; 4:167–173.
123. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502–507.
124. Kawano H, Toyoda K, Miyata S, et al. Heparin-induced thrombocy-topenia: a serious complication of heparin therapy for acute stroke.
Cerebrovasc Dis 2008; 26: 641–649.
125. Kawano H, Yamamoto H, Miyata S, et al. Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute isch-aemic stroke patients. Br J Haematol 2011; 154: 378–386.
126. Miyata S, Yamamoto H, Kamei M, et al. Heparin-induced thrombo-cytopenia clinical studies and the efficacy of argatroban in Japan.
Semin Thromb Hemost 2008; 34(Suppl 1): 37–47.
127. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 t’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–765.
128. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Phy-sicians Evidence-Based Clinical Practice Guidelines. Chest 2012;
141: e495S–e530S.
129. Gao L, Taha R, Gauvin D, et al. Postoperative cognitive dysfunction after cardiac surgery. Chest 2005; 128: 3664–3670.
130. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal as-sessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001; 344: 395–402.
131. Jensen B, Hughes P, Rasmussen L, et al. Cognitive outcomes in el-derly high-risk patients after off-pump versus conventional coronary artery bypass grafting: a randomized trial. Circulation 2006; 113:
2790–2795.
132. Eishi K, Kawazoe K, Kuriyama Y, et al. Surgical management of in-fective endocarditis associated with cerebral complications.
Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg 1995; 110: 1745–1755.
133. Piper C, Wiemer M, Schulte H, et al. Stroke is not a contraindication for urgent valve replacement in acute infective endocarditis. J Heart Valve Dis 2001; 10: 703–711.
134. Segal A, Abernethy W, Palacios I, et al. Stroke as a complication of cardiac catheterization: risk factors and clinical features. Neurology 2001; 56: 975–977.
135. Jones EF, Kalman JM, Calafiore P, et al. Proximal aortic atheroma.
An independent risk factor for cerebral ischemia. Stroke 1995; 26:
218–224.
136. Ohki S, Kubota I, Aizawa K, et al. Aortogenic cerebrovascular acci-dent. Interact Cardiovasc Thorac Surg 2009; 9: 899–900.
137. Merz B. New Framingham data indicate that smoking is also a risk factor for stroke. JAMA 1987; 257: 2132, 2134
138. Kannel WB. Cardiovascular hazards of components of blood pres-sure. J Hypertens 2002; 20: 395–397.
139. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort stud-ies. Arch Intern Med 2000; 160: 939–944.
140. Greenberg JA, Chow G, Ziegelstein RC. Caffeinated coffee con-sumption, cardiovascular disease, and heart valve disease in the el-derly (from the Framingham Study). Am J Cardiol 2008; 102: 1502–
1508.
141. Freedman ND, Park Y, Abnet CC, et al. Association of coffee drink-ing with total and cause-specific mortality. N Engl J Med 2012; 366:
1891–1904.
142. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011;
364: 1218–1229.
143. Ohkubo T, Hozawa A, Nagatomi R, et al. Effects of exercise train-ing on home blood pressure values in older adults: a randomized controlled trial. J Hypertens 2001; 19: 1045–1052.
144. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002; 347: 716–725.
145. Goodyear LJ. The exercise pill--too good to be true? N Engl J Med 2008; 359: 1842–1844.
146. 日本透析医学会．維持血液透析ガイドライン：血液透析導入．
透析会誌2013; 46: 1107–1155.
147. National-Kidney-Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratifica-tion. Am J Kidney Dis 2002; 39 (2 suppl 1): S1–S266.
148. Sarnak M, Levey A, Schoolwerth A, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovas-cular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–
2169.
149. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1–150.
150. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073–2081.
151. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes
Chronic Kidney Disease Guideline Development Work Group Mem-bers. Evaluation and management of chronic kidney disease: synop-sis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825–830.
152. 日本腎臓学会編．CKD診療ガイド2012．東京医学社，2012．
153. Weiner D, Tabatabai S, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48: 392–401.
154. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisaya-ma Study. Kidney Int 2005; 68: 228–236.
155. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, se-rum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:
1264–1271.
156. Ito S, Nagasawa T, Abe M, et al. Strain vessel hypothesis: a view-point for linkage of albuminuria and cerebro-cardiovascular risk.
Hypertens Res 2009; 32: 115–121.
157. Ito S. Cardiorenal syndrome: an evolutionary point of view. Hyper-tension 2012; 60: 589–595.
158. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Jap-anese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:
982–992.
159. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009;
13: 621–630.
160. Di Angelantonio E, Danesh J, Eiriksdottir G, et al. Renal function and risk of coronary heart disease in general populations: new pro-spective study and systematic review. PLoS Med 2007; 4: e270.
161. Shihara M, Tsutsui H, Tsuchihashi M, et al; Japanese Coronary In-vention Study (JCIS) Group. In-hospital and one-year outcomes for patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2002; 90: 932–936.
162. Yamaguchi J, Kasanuki H, Ishii Y, et al; HIJC Study Group. Prog-nostic significance of serum creatinine concentration for in-hospital mortality in patients with acute myocardial infarction who under-went successful primary percutaneous coronary intervention (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI]
Registry). Am J Cardiol 2004; 93: 1526–1528.
163. Anavekar N, McMurray J, Velazquez E, et al. Relation between re-nal dysfunction and cardiovascular outcomes after myocardial in-farction. N Engl J Med 2004; 351: 1285–1295.
164. Tokmakova M, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110: 3667–3673.
165. Inaguma D, Tatematsu M, Hibiki S, et al. Relationship between re-nal function at the time of percutaneous coronary intervention and prognosis in ischemic heart disease patients. Clin Exp Nephrol 2007;
11: 56–60.
166. Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardio-vascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006; 17: 2886–2891.
167. Assali A, Brosh D, Ben-Dor I, et al. The impact of renal insufficien-cy on patients’ outcomes in emergent angioplasty for acute myocar-dial infarction. Catheter Cardiovasc Interv 2007; 69: 395–400.
168. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659–
169. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission 663.
of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001; 88: 530–
170. McAlister F, Ezekowitz J, Tonelli M, et al. Renal insufficiency and 533.
heart failure: prognostic and therapeutic implications from a pro-spective cohort study. Circulation 2004; 109: 1004–1009.
171. Hillege H, Girbes A, de Kam P, et al. Renal function, neurohormon-al activation, and survivneurohormon-al in patients with chronic heart failure. Cir-culation 2000; 102: 203–210.
172. Hillege H, Nitsch D, Pfeffer M, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circu-lation 2006; 113: 671–678.
173. Ahmed A, Rich M, Sanders P, et al. Chronic kidney disease associ-ated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol 2007; 99: 393–398.
174. Silverberg D, Wexler D, Blum M, et al. The cardio-renal anaemia syndrome: does it exist? Nephrol Dial Transplant 2003; 18 (Suppl